Physio 4.5

Cardiovascular Disease (CVD): Overview

  • Public Health Impact: CVD is the leading cause of death for both men and women in the United States and represents a significant public health burden.

  • Economic Cost: The annual cost associated with CVD exceeds 200 billion200 \text{ billion}, accounting for healthcare services, medications, and lost productivity.

  • Pathological Context: It is a major contributor to and consequence of various physiological disruptions, including hyperlipidemia, atherosclerosis, and hypertension.

Hyperlipidemia and Lipoproteins

  • Definitions and Classification:

    • Hyperlipidemia: An excess of lipids in the blood. Lipids include triglycerides, phospholipids, and cholesterol.

    • Hypercholesterolemia: Specifically refers to elevated levels of blood cholesterol. For medical purposes in this context, the terms hypercholesterolemia and hyperlipidemia are often used interchangeably.

  • Lipoprotein Structure and Function:

    • As cholesterol and triglycerides are insoluble in plasma, they require a stabilizing coat made of water-soluble phospholipids and proteins.

    • Apoproteins: The protein component that stabilizes the lipid particle.

    • Lipoproteins: The combined particle consisting of lipids and apoproteins. They transport lipids to tissues for energy utilization, lipid deposition, steroid hormone production, and bile acid formation.

    • Density Relationship: Lipoproteins are named by density. Proteins are denser than fats; therefore, as the protein content (density) increases, the triglyceride density decreases.

  • Types of Lipoproteins:

    • Chylomicrons: The largest particles; primarily carry triglycerides, with small amounts of phospholipids, cholesterol, and apoprotein B.

    • Very-Low-Density Lipoprotein (VLDL): Primarily carries triglycerides.

    • Intermediate-Density Lipoprotein (IDL): A transitional lipoprotein.

    • Low-Density Lipoprotein (LDL): Known as "bad cholesterol." It is the primary carrier of cholesterol. Approximately 70%70\% of LDL is removed from circulation by LDL receptors; the remainder is handled by monocytes/macrophages (scavenger cells).

    • High-Density Lipoprotein (HDL): Known as "good cholesterol." It carries cholesterol away from peripheral tissues back to the liver for excretion. There is an inverse relationship between HDL levels and atherosclerosis risk.

  • Lipoprotein Synthesis: Occurs primarily in the small intestine and the liver.

Clinical Presentation and Diagnostics of Hyperlipidemia

  • Factors Raising Blood Lipids: Elevated levels result from a multifactorial mix of nutrition, genetics, medications, comorbid conditions, and metabolic diseases.

  • Primary vs. Secondary Hypercholesterolemia:

    • Primary: Develops independently of other health problems, often due to genetic defects (synthesis of apoproteins, lack of/defective receptors, or intracellular cholesterol handling).

    • Secondary: Associated with other health problems or behaviors such as obesity, high-calorie intake, diabetes mellitus, hypothyroidism, nephrotic syndrome, and obstructive liver disease.

  • Familial Hypercholesterolemia (Type 2A):

    • An autosomal dominant disorder caused by deficient or defective LDL receptors.

    • Heterozygote levels: 250−500 mg/dL250-500 \text{ mg/dL}.

    • Homozygote levels: can exceed 1000 mg/dL1000 \text{ mg/dL}.

    • Xanthomas: Characteristic cholesterol deposits appearing in the skin, cornea, and tendons.

  • Drug-Induced Lipid Elevation: Medications such as beta-blockers, estrogens, and protease inhibitors (for HIV) can raise lipid levels.

  • NCEP Fasting Lipoprotein Profile Recommendations:

    • The National Cholesterol Education Program (NCEP) recommends all adults aged 2020 and older have a profile measured once every 5 years5 \text{ years}.

  • Classification of Blood Lipid Levels (Table 4.3):

    • LDL Cholesterol:

      • Optimal: <100 mg/dL<100 \text{ mg/dL}

      • Near/Above Optimal: 100−129 mg/dL100-129 \text{ mg/dL}

      • Borderline High: 130−159 mg/dL130-159 \text{ mg/dL}

      • High: 160−189 mg/dL160-189 \text{ mg/dL}

      • Very High: ≥190 mg/dL\ge 190 \text{ mg/dL}

    • Total Cholesterol:

      • Desirable: <200 mg/dL<200 \text{ mg/dL}

      • Borderline High: 200−239 mg/dL200-239 \text{ mg/dL}

      • High: ≥240 mg/dL\ge 240 \text{ mg/dL}

    • HDL Cholesterol:

      • Low: <40 mg/dL<40 \text{ mg/dL}

      • High: ≥60 mg/dL\ge 60 \text{ mg/dL}

    • Triglycerides:

      • Normal: <150 mg/dL<150 \text{ mg/dL}

      • Borderline High: 150−199 mg/dL150-199 \text{ mg/dL}

      • High: 200−499 mg/dL200-499 \text{ mg/dL}

Hyperlipidemia Management

  • Primary Target: Reduction in LDL cholesterol, particularly for those at risk for coronary heart disease (CHD).

  • Risk Factors for CHD: Smoking, hypertension, family history of premature CHD (first-degree relative), age (men ≥45\ge 45; women ≥55\ge 55), and HDL <40 mg/dL<40 \text{ mg/dL}.

  • Lifestyle Changes: Usually trialed for 3 months3 \text{ months} before drug therapy (except in high-risk patients like those with diabetes).

    • Physical Activity: Increase regular exercise.

    • Weight Reduction and Smoking Cessation.

    • Dietary Restrictions: Decrease excess calories; saturated fat <7%<7\% of total daily intake; trans fats <1%<1\% of daily intake; cholesterol <300 mg/day<300 \text{ mg/day}; lower consumption of sugars, salt, and alcohol.

    • Dietary Emphasis: Fruits, vegetables, and fish.

  • Pharmacologic Treatment:

    • HMG CoA Reductase Inhibitors (Statins): (e.g., atorvastatin, rosuvastatin, simvastatin). Block hepatic synthesis of cholesterol. First-line for LDL reduction; also decrease triglycerides and increase HDL.

    • Bile Acid-binding Resins: (e.g., cholestyramine, colestipol, colesevelam). Sequester bile acids in the intestine, forcing the liver to use more blood cholesterol to synthesize new bile acids. Used as an adjunct to statins (increases HDL 3−5%3-5\%).

    • Niacin (Vitamin B3): Blocks VLDL synthesis. Lowers VLDL, IDL, and LDL while increasing HDL (15−35%15-35\%). Side effects include flushing and headache.

    • Fibrates: (e.g., fenofibrate, gemfibrozil). Decrease VLDL synthesis and increase triglyceride clearance from circulation (reduces triglycerides by 20−50%20-50\%).

    • Cholesterol Absorption Inhibitor Agents: Direct intervention on dietary cholesterol intake.

Atherosclerosis: Pathology and Progression

  • Etymology: From Greek atheros ("gruel/paste") and sclerosis ("hardness").

  • Definition: A hardening of the arteries characterized by fibrofatty lesions in the lining of medium and large arteries (aorta, coronary arteries, large vessels supplying the brain).

  • Lesion Types:

    1. Fatty Streaks: Thin, flat, yellow lines composed of macrophages and smooth muscle cells distended with lipids (foam cells). Present in childhood; can regress or develop into plaques.

    2. Fibrous Atheromatous Plaques: The basic lesion of clinical atherosclerosis. Gray/pearly white appearance due to ingested oxidized lipoproteins. Consists of smooth muscle cells, macrophages, leukocytes, extracellular matrix (collagen, elastic fibers), and lipids. Occludes the vessel lumen.

    3. Complicated Lesions: Occur when plaques break open, leading to hemorrhage, ulceration, and scar tissue. These trigger thrombosis.

  • Risk Factors:

    • Nonmodifiable: Increasing age, male gender, genetic disorders of lipid metabolism, family history of premature CAD.

    • Modifiable: Hyperlipidemia (elevated LDL, low HDL), cigarette smoking (causes endothelial damage), hypertension, obesity, diabetes mellitus.

    • Risk Multiplication: HTN or diabetes doubles risk; having both increases risk eight-fold.

  • Nontraditional/Inflammatory Markers:

    • C-reactive protein (CRP): General indicator of inflammation; elevated levels are associated with vascular disease.

    • Lipoprotein(a): Similar to LDL; promotes foam cell formation and cholesterol deposition in plaques.

  • Vessel Vulnerability: "Unstable plaques" have a large central lipid core, inflammatory infiltrate, and a thin fibrous cap, making them prone to rupture.

  • Clinical Complications: Typically appear 20−40 years20-40 \text{ years} after development begins. Complications include ischemia, infarction, aneurysm (weakening of the vessel wall), and thrombus/emboli formation.

Hypertension: Guidelines and Classifications

  • The "Silent Killer": Patients are often asymptomatic until target-organ damage occurs (heart, eyes, kidneys, blood vessels).

  • JNC 8 Guidelines (Table 4.5):

    • Normal: <120/<80 mm Hg<120 / <80 \text{ mm Hg}

    • Elevated: 120−129/<80 mm Hg120-129 / <80 \text{ mm Hg}

    • Hypertension Stage 1: 130−139 mm Hg130-139 \text{ mm Hg} systolic OR 80−89 mm Hg80-89 \text{ mm Hg} diastolic.

    • Hypertension Stage 2: ≥140 mm Hg\ge 140 \text{ mm Hg} systolic OR ≥90 mm Hg\ge 90 \text{ mm Hg} diastolic.

    • Hypertensive Crisis:

      • Urgency: >180 mm Hg>180 \text{ mm Hg} systolic and/or >120 mm Hg>120 \text{ mm Hg} diastolic.

      • Emergency: >180/>120 mm Hg>180 / >120 \text{ mm Hg} with evidence of target organ damage. Requires ICU and IV treatment.

  • Risk Factors:

    • Non-modifiable: Family history (50%50\% contribution), age, race (higher incidence in African Americans).

    • Modifiable: Obesity, high salt intake (American average is 9−12 g/day9-12 \text{ g/day}; recommended is 6 g/day6 \text{ g/day}), excessive alcohol, and low potassium intake.

    • Other conditions: Insulin resistance, obstructive sleep apnea, and secondary causes (renal artery stenosis, aldosteronism).

Clinical Manifestations and Management of Hypertension

  • Impact on the Heart: Increased workload leads to Left Ventricular Hypertrophy, a major risk factor for death.

  • Organ Damage:

    • Kidneys: Nephrosclerosis and hypoperfusion of the glomerulus.

    • Brain: Narrowing/sclerosis of small arteries, increasing risk of ischemic stroke, hemorrhage, dementia, and cognitive impairment.

    • Eyes: Hypertensive retinopathy, microvascular changes, papilledema, and arteriovenous (AV) nicking.

  • Diagnosis Protocols:

    • Measured on at least two separate occasions.

    • Patient must be rested for 5 minutes5 \text{ minutes}, with an empty bladder, and no smoking/caffeine/exercise for 30 minutes30 \text{ minutes} prior.

    • White Coat Hypertension: Elevated readings in-office due to nervousness; requires monitoring in different settings.

  • Lifestyle Modifications (Table 4.6):

    • Weight Reduction: BMI 18.5−24.918.5-24.9; reduces BP by 5−20 mm Hg5-20 \text{ mm Hg} per 10 kg10 \text{ kg} lost.

    • DASH Eating Plan: High in fruits, vegetables, low-fat dairy; low in saturated/total fat (8−14 mm Hg8-14 \text{ mm Hg} reduction).

    • Sodium Reduction: Limit to 2.4 g2.4 \text{ g} sodium or 6 g6 \text{ g} sodium chloride (2−8 mm Hg2-8 \text{ mm Hg} reduction).

    • Physical Activity: 30 minutes30 \text{ minutes} aerobic activity most days (4−9 mm Hg4-9 \text{ mm Hg} reduction).

    • Alcohol Moderation: Limit to 2 drinks2 \text{ drinks} (men) or 1 drink1 \text{ drink} (women) per day (2−4 mm Hg2-4 \text{ mm Hg} reduction).

  • Pharmacologic Agents:

    • Thiazide Diuretics: Decrease vascular volume and cardiac output by inhibiting sodium reabsorption.

    • ACE Inhibitors: Block conversion of Angiotensin I to Angiotensin II; reduces vasoconstriction and aldosterone.

    • ARBs (Angiotensin II Receptor Blockers): Prevent Angiotensin II from binding to receptors.

    • CCBs (Calcium Channel Blockers): Inhibit calcium movement into cardiac/vascular smooth muscle; cause vasodilation and decreased heart rate/contractility.

    • Beta-blockers: Now considered second-line therapy.